Fortitude Reports Financial And Operating Results For The Nine Months Ended September 30, 2026
| GAAP Net Income to Adj. EBITDA Reconciliation | ||
| $ in millions | ||
| Nine-Months Ended September 30, 2026 | ||
| Net Income (Loss) | ($16.2 | ) |
| plus: Depreciation and amortization | 15.0 | |
| plus: Income tax benefit | (2.2 | ) |
| plus: Interest expenses | 0.5 | |
| EBITDA | ( $3.0 | ) |
| plus: Non-recurring litigation related expenses | 1.2 | |
| plus: Non-recurring transaction related expenses1 | 8.5 | |
| plus: Impairment of miners | 10.3 | |
| plus: Loss on sale of ZEC received from DCG Credit Facility2 | 0.1 | |
| less: Change in fair value of equity securities3 | (0.7 | ) |
| plus: Realized gain/loss on disposal of equipment | 0.7 | |
| Adjusted EBITDA | $ 17.1 |
(1) Non-recurring expenses related to the proposed business combination with HeartSciences and Fortitude's previous spin-out from Foundry Digital, LLC, including advisory, legal, accounting, and regulatory fees.
(2) Represents a loss recognized upon sale of Zcash received in connection with a borrowing under the DCG credit facility, which we liquidated for cash in order to make a payment to Bitmain for miner deposits.
(3) Represents change in fair value of shares of HeartSciences' common stock acquired by Fortitude in a private placement pursuant to the subscription agreement dated August 12, 2026 (the“PIPE Investment”) as these shares will not be contributed to Fortitude Mining HoldCo, LLC in connection with the proposed business combination with HeartSciences.
Proposed Business Transaction
As previously announced on June 23, 2026, Fortitude and HeartSciences Inc. (Nasdaq: HSCS), an AI-powered medical technology company, entered into a definitive agreement providing for a proposed business combination (the "Proposed Transaction"). HeartSciences has scheduled a special meeting of its stockholders for November 19, 2026, to vote on the Proposed Transaction, which is expected to close in the fourth quarter of 2026, subject to stockholder approval and the satisfaction of other closing conditions. Following the closing, DCG is expected to own approximately 94% of the combined company on a fully diluted basis.
About Fortitude
Fortitude is establishing a new category of public infrastructure as the premier vertically integrated Zcash mining platform. Upon closing of its Proposed Transaction with HeartSciences, the Company expects to commence trading on the Nasdaq under the ticker TUDE. Like Bitcoin, Zcash relies on secure proof of work mining, but it uniquely powers the privacy economy by validating transactions without exposing underlying financial data. Upon its market debut, Fortitude expects to offer investors a publicly listed vehicle for direct exposure to this growing ecosystem. Driven by a seasoned management team, the Company pairs self-mining operations with an owned data center footprint and a controlled power portfolio to scale high conviction opportunities across the broader digital asset landscape.
For more information, visit Fortitude Mining and follow Fortitude on X at @FortitudeCrypto.
In the ordinary course of business, Fortitude currently sells or otherwise monetizes all the digital assets that it mines, including ZEC. In addition, Fortitude and its affiliates and subsidiaries, including DCG, from time to time sell, pledge or otherwise monetize their digital asset holdings, including ZEC. The funds received from such sales, pledges, or other monetization activities are used to fund operating expenses and capital investments, as well as for other purposes, including to hedge exposures and realize investment gains.
Cautionary Note Regarding Forward-Looking Information
This press release contains forward-looking statements. These forward-looking statements generally can be identified by the use of words such as“expect,”“plan,”“will,”“would,”“believe,”“intend,”“potential,”“may,”“designed,”“anticipate” and other words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, express or implied statements relating to Fortitude and its plans and expectations concerning the letter of intent with BITMAIN, the expected delivery of Antminer Z15 Pro units, the expectation that the Proposed Transaction will bring Fortitude to the public markets and the expected timing of the Proposed Transaction, the expected leadership of the combined company and DCG's expected ownership of the combined company. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
These forward-looking statements are based on management's current expectations and assumptions as of the date of this press release and are subject to a number of known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements, including, without limitation, the following: the risk that the Proposed Transaction may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the Proposed Transaction, including obtaining the requisite approval of the HeartSciences shareholders; market, macroeconomic, or other conditions that could adversely affect either HeartSciences or Fortitude, or the combined company; risks related to the integration of the two companies and the management of a newly public company; risks relating to Fortitude's operations and business, including the highly volatile nature of the price of Zcash and other cryptocurrencies; and risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally. Additional factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release are discussed in the definitive proxy statement filed on Schedule 14A by HeartSciences with the U.S. Securities and Exchange Commission (“SEC”) in connection with the Proposed Transaction on October 19, 2026 (the“Definitive Proxy Statement”), HeartSciences' 2026 Annual Report on Form 10-K, filed with the SEC on July 23, 2026, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026, filed with the SEC on September 14, 2026, and other HeartSciences' reports filed with the SEC from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. All forward-looking statements are made as of the date of this press release.
Non-GAAP Financial Measures
EBITDA & Adjusted EBITDA
Fortitude has presented certain financial measures that are not recognized under GAAP. Specifically, Fortitude has presented“EBITDA” and“Adjusted EBITDA” (each as further described below). References to“EBITDA” mean earnings before interest, taxes, depreciation and amortization and“Adjusted EBITDA” means EBITDA, adjusted for non-recurring litigation related expenses, non-recurring Proposed Transaction related expenses and non-recurring expenses related to Fortitude's previous spin-out from Foundry Digital, LLC (including advisory, legal, accounting, and regulatory fees), impairment of miners, loss on DCG credit facility Zcash proceed sales, loss on disposal of equipment, and change in fair value of equity securities Fortitude holds from the PIPE Investment. Fortitude uses non-GAAP measures in its operational and financial decision making and believes that such non-GAAP numbers are more representative of the performance of the business and thus instructive for its strategic planning. Specifically, with respect to Adjusted EBITDA, Fortitude believes it is useful to exclude certain items in order to allow for period-over-period comparisons on a more consistent basis and to focus on what Fortitude regards to be a more meaningful indicator for evaluating the underlying operating performance of the business. Fortitude believes that these non-GAAP financial measures, while not a substitute for GAAP financial measures, provide investors with (i) an improved ability to evaluate Fortitude's underlying performance and (ii) greater transparency of the key performance metrics used by management with respect to operational and financial decision making. In evaluating Adjusted EBITDA, you should be aware that in the future Fortitude may incur expenses that are the same as or similar to some of the adjustments in such presentation. The non-GAAP financial measures presented herein are provided as supplemental information to Fortitude's performance measures calculated in accordance with GAAP and should not be considered in isolation or as a substitute for GAAP. Non-GAAP measures have limitations as an analytical tool. Some of these limitations are: (i) Adjusted EBITDA excludes certain transaction related expenses and non-recurring legal expenses Fortitude has incurred, such as litigation costs and one-time accounting charges; (ii) although depreciation, amortization, impairments, and equipment disposal losses are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and the cash requirements for such replacements are not reflected in Adjusted EBITDA; (iii) the omission of the amortization expense associated with Fortitude's intangible assets further limits the usefulness of Adjusted EBITDA; and (iv) Adjusted EBITDA does not include the payment of taxes, which is a necessary element of Fortitude's operations. Because of these limitations, such non-GAAP measures should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Management compensates for these limitations by not viewing the non-GAAP measures in isolation and specifically by using other GAAP measures to measure Fortitude's operating performance. Further, non-GAAP financial measures do not have any standardized meaning prescribed under GAAP and therefore may not be comparable to other issuers. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, Fortitude's results of operations as determined in accordance with GAAP.
Additional Information About the Proposed Transaction and Where to Find It
This press release may be deemed solicitation material in respect of the Proposed Transaction. In connection with the Proposed Transaction, on October 19, 2026, HeartSciences filed a definitive proxy statement on Schedule 14A (the“Definitive Proxy Statement”) with the SEC, and may file additional relevant materials with the SEC from time to time. HeartSciences has mailed the Definitive Proxy Statement and a proxy card to each shareholder entitled to vote at the special meeting relating to the Proposed Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT HEARTSCIENCES HAS FILED OR MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED TRANSACTION. THIS PRESS RELEASE DOES NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION AND RELATED MATTERS AND IS NOT INTENDED TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF SUCH MATTERS. The Definitive Proxy Statement, the preliminary proxy statement and other relevant materials in connection with the Proposed Transaction (when they become available), and any other documents filed by HeartSciences with the SEC, may be obtained free of charge at the SEC's website at In addition, investors and shareholders may obtain free copies of the documents filed with the SEC or by sending a request to the HeartSciences Investor Relations Department at....
Participants in the Solicitation
HeartSciences and Fortitude, their respective directors and executive officers, and certain executive officers of DCG may be deemed to be participants in the solicitation of proxies from HeartSciences' shareholders with respect to the Proposed Transaction. Information regarding the identity of the potential participants, and their direct or indirect interests in the Proposed Transaction, by security holdings or otherwise, is set forth in the Definitive Proxy Statement and other materials that have been or may be filed with the SEC in connection with the Proposed Transaction.
No Offer or Solicitation
This press release and the information contained herein is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. The Proposed Transaction will be implemented solely pursuant to the terms and conditions of the merger agreement, which contain the full terms and conditions of the Proposed Transaction.
Contacts
Investor Relations and Media Contact:
ICR
Phone: 917-375-9457
Email: ...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment